BridgeBio is significantly advanced the progress of the new therapy for ATTR-CM, leveraging the compound. Initial clinical data indicates significant outcomes for those diagnosed by the serious condition. The emphasis highlights BridgeBio's focus to addressing unmet patient needs in a heart disea